Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH).
María Del Mar GutierrezIsabel MurMaría Gracia MateoFrancesc VidalPere DomingoPublished in: Expert opinion on pharmacotherapy (2021)
Management of COVID-19 in PLWH is no different from the general population. It should be based on careful supportive care, emphasizing lung-protective ventilation, and wise pharmacological interventions. The antiviral drug remdesivir and dexamethasone are the only pharmacological interventions with clinical benefit for COVID-19, whereas anticoagulation may prevent thrombotic complications. The experience with using these drugs in PLWH is limited, which prevents from rendering well-founded conclusions. Until more data on COVID-19 in PLWH become available, the best weapons within our reach are sound supportive care and sensible use of RDV and dexamethasone, bearing in mind the potential for drug-drug interactions of most corticosteroids and antiretroviral drugs.
Keyphrases
- coronavirus disease
- sars cov
- healthcare
- palliative care
- physical activity
- respiratory syndrome coronavirus
- low dose
- high dose
- hiv infected
- quality improvement
- human immunodeficiency virus
- drug induced
- venous thromboembolism
- atrial fibrillation
- mouse model
- hiv positive
- risk assessment
- intensive care unit
- chronic pain
- hepatitis c virus
- antiretroviral therapy
- adverse drug
- mechanical ventilation
- hiv infected patients
- deep learning
- artificial intelligence
- human health